Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients with involvement of at least 2 anatomical areas at screening and baseline~* Patients need to have an IGA hand and foot score of 3 or 4 (moderate-to-severe disease) at screening and baseline~* Patients with documented recent history (within 6 months before the screening visit) of inadequate response of atopic hand and foot dermatitis to topical medication(s)~* Patients meet the diagnosis criteria for atopic dermatitis (AD)~* Provide informed consent/assent signed by study patient or legally acceptable representative~* Patients need to have been compliant with the skin protection measures through the entire duration of the screening period~Key Exclusion Criteria:~* Treatment with dupilumab in the past~* Patients with a positive patch test reaction that are deemed to be clinically relevant as the current cause of the hand and foot dermatitis~* Patients with documented exposure to irritants believed to be a predominant cause of the current hand and foot dermatitis~* Treatment with systemic corticosteroids or non-steroidal immunosuppressive drugs within 4 weeks prior to baseline~* Known history of HIV/HBV/HCV infection~* Pregnant or breastfeeding women or planning to become pregnant or breastfeed during the patient's participation in this study~* Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment and during the study~NOTE: Other protocol defined inclusion / exclusion criteria apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dupilumab (Type: EXPERIMENTAL): Administered subcutaneously (SC) once every 2 weeks (Q2W), following a loading dose on Day 1
- Matching Placebo (Type: EXPERIMENTAL): Administered SC Q2W, following a loading dose on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).